BRONX, New York, Oct. 28 [TNSmedicalresearch - Clinical Cancer Research] -- Yeshiva University's Albert Einstein College of Medicine issued the following news release:

In the bone-marrow cancer myelodysplastic syndrome (MDS), anemia occurs because the proliferation of abnormal blood cells leaves people with too few normal ones. An experimental cancer drug called galunisertib may offer a way to anemia in low-to-intermediate risk MDS patients without the need for blood transfusions.

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Submit Form Click here for more information about our products